Virpax Pharmaceuticals (VRPX) Competitors $0.73 +0.01 (+1.38%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VRPX vs. LGVN, PMCB, NRXP, INAB, INDP, CLDI, ALZN, WENA, AYTU, and TSBXShould you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Longeveron (LGVN), PharmaCyte Biotech (PMCB), NRx Pharmaceuticals (NRXP), IN8bio (INAB), Indaptus Therapeutics (INDP), Calidi Biotherapeutics (CLDI), Alzamend Neuro (ALZN), ANEW Medical (WENA), Aytu BioPharma (AYTU), and Turnstone Biologics (TSBX). These companies are all part of the "pharmaceutical products" industry. Virpax Pharmaceuticals vs. Longeveron PharmaCyte Biotech NRx Pharmaceuticals IN8bio Indaptus Therapeutics Calidi Biotherapeutics Alzamend Neuro ANEW Medical Aytu BioPharma Turnstone Biologics Virpax Pharmaceuticals (NASDAQ:VRPX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership. Does the media prefer VRPX or LGVN? In the previous week, Longeveron had 4 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 6 mentions for Longeveron and 2 mentions for Virpax Pharmaceuticals. Longeveron's average media sentiment score of 0.73 beat Virpax Pharmaceuticals' score of 0.44 indicating that Longeveron is being referred to more favorably in the news media. Company Overall Sentiment Virpax Pharmaceuticals Neutral Longeveron Positive Is VRPX or LGVN more profitable? Virpax Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -1,513.83%. Longeveron's return on equity of -237.57% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Virpax PharmaceuticalsN/A -1,554.34% -242.73% Longeveron -1,513.83%-237.57%-140.97% Does the MarketBeat Community prefer VRPX or LGVN? Longeveron received 9 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. Likewise, 92.31% of users gave Longeveron an outperform vote while only 60.00% of users gave Virpax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVirpax PharmaceuticalsOutperform Votes360.00% Underperform Votes240.00% LongeveronOutperform Votes1292.31% Underperform Votes17.69% Which has more volatility and risk, VRPX or LGVN? Virpax Pharmaceuticals has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Do analysts rate VRPX or LGVN? Virpax Pharmaceuticals presently has a consensus target price of $3.00, suggesting a potential upside of 317.25%. Longeveron has a consensus target price of $8.00, suggesting a potential upside of 270.37%. Given Virpax Pharmaceuticals' higher possible upside, equities research analysts plainly believe Virpax Pharmaceuticals is more favorable than Longeveron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Longeveron 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of VRPX or LGVN? 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 4.2% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 19.1% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has stronger valuation & earnings, VRPX or LGVN? Virpax Pharmaceuticals has higher earnings, but lower revenue than Longeveron. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/ALongeveron$1.23M25.24-$21.41M-$8.74-0.25 SummaryLongeveron beats Virpax Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Ad DarwinDon’t Miss Out! Get 2 Hot AI Stocks for Under $10/Share 🚀Artificial Intelligence (AI) stocks are booming, and now is your chance to get in on the action — without breaking the bank! We’ve just uncovered 2 must-buy AI stocks trading for under $10/share, and they’re showing serious potential for growth.Click here to get your FREE report delivered instantly! Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRPX vs. The Competition Export to ExcelMetricVirpax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.51M$7.20B$5.41B$8.61BDividend YieldN/A8.77%5.22%4.20%P/E RatioN/A16.37141.1017.75Price / SalesN/A363.711,532.1394.15Price / CashN/A50.1638.9333.56Price / Book0.445.744.784.64Net Income-$15.19M$151.16M$115.44M$225.71M7 Day Performance15.95%-0.10%0.33%0.66%1 Month Performance3.54%7.86%4.83%2.80%1 Year Performance-89.95%40.54%39.74%34.26% Virpax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRPXVirpax Pharmaceuticals1.7095 of 5 stars$0.73+1.4%$3.00+309.3%-90.0%$3.58MN/A0.007LGVNLongeveron3.0998 of 5 stars$2.18-1.4%$8.00+267.0%-88.8%$13.84M$1.23M-0.2520Short Interest ↓PMCBPharmaCyte Biotech1.466 of 5 stars$1.80flatN/A-10.5%$13.82MN/A2.732Gap DownNRXPNRx Pharmaceuticals2.1749 of 5 stars$1.29+6.6%$31.50+2,341.9%-95.7%$13.80MN/A-0.482Gap UpINABIN8bio4.0575 of 5 stars$0.30-3.2%$10.00+3,223.4%-71.5%$13.28MN/A-0.3620Short Interest ↓Positive NewsINDPIndaptus Therapeutics3.9325 of 5 stars$1.54+14.1%$12.00+679.2%-42.6%$13.15MN/A-0.836Upcoming EarningsShort Interest ↓Gap DownCLDICalidi Biotherapeutics2.3358 of 5 stars$1.18+8.3%$16.67+1,312.4%N/A$13.11M$50,000.000.0041Gap DownHigh Trading VolumeALZNAlzamend Neuro0.7254 of 5 stars$1.63+1.2%N/A-92.0%$13.01MN/A-1.654Gap UpWENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpAYTUAytu BioPharma1.2314 of 5 stars$2.08-3.7%N/A-25.5%$12.44M$81.00M-0.73160Short Interest ↓Positive NewsTSBXTurnstone Biologics3.8085 of 5 stars$0.54+3.9%$2.13+297.2%-80.8%$12.38M$19.31M-0.1582Positive News Related Companies and Tools Related Companies LGVN Alternatives PMCB Alternatives NRXP Alternatives INAB Alternatives INDP Alternatives CLDI Alternatives ALZN Alternatives WENA Alternatives AYTU Alternatives TSBX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRPX) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.